GSA Capital Partners LLP Has $226,000 Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

GSA Capital Partners LLP lowered its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 15.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,994 shares of the company’s stock after selling 880 shares during the quarter. GSA Capital Partners LLP’s holdings in Twist Bioscience were worth $226,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Signaturefd LLC grew its stake in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new stake in Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. grew its position in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience during the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the last quarter.

Twist Bioscience Stock Performance

TWST opened at $42.23 on Monday. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -11.73 and a beta of 1.78. The firm’s 50-day simple moving average is $43.78 and its 200-day simple moving average is $46.15. Twist Bioscience Co. has a twelve month low of $23.07 and a twelve month high of $60.90.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent research reports. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Scotiabank lifted their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI boosted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.78.

Insiders Place Their Bets

In related news, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the sale, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dennis Cho sold 659 shares of Twist Bioscience stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.